Showing results (81-90 of 599) with videos related to
Sort By:
Pageof 60
Nature Structural & Molecular Biology|October 3, 2017
Nuclear topology modulates the mutational landscapes of cancer genomesKyle S Smith, Lin L Liu, Shridar Ganesan, et al.Current Hematologic Malignancy Reports|April 29, 2010
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemiaDavid Dingli, Ayalew TefferiJournal of Theoretical Biology|November 8, 2003
Somatic selection for and against cancerFranziska Michor, Steven A Frank, Robert M May, et al.Biorxiv : the Preprint Server for Biology|July 9, 2024
Functional consequences of a p53-MDM2-p21 incoherent feedforward loopJamie A Dean, Jose Reyes, Michael Tsabar, et al.Haematologica|March 16, 2012
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trialsMin Tang, Jasmine Foo, Mithat Gönen, et al.Journal for Immunotherapy of Cancer|May 9, 2025
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumabChristopher J Graser, Thomas O McDonald, Paul J Catalano, et al.Plos Computational Biology|May 14, 2010
A differentiation-based phylogeny of cancer subtypesMarkus Riester, Camille Stephan-Otto Attolini, Robert J Downey, et al.Biorxiv : the Preprint Server for Biology|February 20, 2025
BESTDR: Bayesian quantification of mechanism-specific drug response in cell cultureThomas O McDonald, Simone Bruno, James P Roney, et al.Plos One|December 6, 2011
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemiaKevin Leder, Jasmine Foo, Brian Skaggs, et al.Cancer Research|November 17, 2025
BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug ResponsesThomas O McDonald, Simone Bruno, James P Roney, et al.Pageof 60